Publications

Iryna Shlyakhovska, senior associate at Legal Alliance CompanyThe Cabinet of Ministers of Ukraine by Resolution No. 295 of April 26th, 2017 approved the Procedu

The Antimonopoly Committee of Ukraine issued a report for 2016. The first thing that catches our eye is form of the report. This is the first report of the Antimonopoly Committee of Ukraine, and indeed the first report of a state body (at least from those that I have seen) presented in a graphic illustrative form.

Since the beginning of 2017, there have been discussions, including at the level of the Committee of the Verkhovna Rada of Ukraine on Healthcare, on the feasibility of procurement of medicinal products and medical devices through international specialized organizations.

​In the beginning of the 2017 our company ran a survey among the clients, mostly international pharmaceutical companies and their representative offices in Ukraine, to define the main challenges of the pharmaceutical market in Ukraine of 2016.

The entry into force of amendments to the TRIPS allows the developed states to issue compulsory licenses to generic pharmaceutical companies for the production of medicinal products, allowing them to export the product to developing countries. This mechanism is very interesting for the domestic pharmaceutical industry.

One of the most high-profile events of healthcare area in Ukraine in 2015 was the introduction of the mechanism of international procurement of medicinal products and medical devices through international specialized organizations.

Legal Alliance lawyers speak on the practice of domain disputes solutions in Ukraine and Europe.

Pro Bono services in Ukraine, unlike Western Europe or the United States, can only be described as not very popular and for some Ukrainian law firms it is a completely unknown phenomenon.